Literature DB >> 18025216

Characterization of the deregulated immune activation occurring at late stages of mycobacterial infection in TNF-deficient mice.

Manuela Flórido1, Rui Appelberg.   

Abstract

In the absence of TNF, mice infected with Mycobacterium avium suffer a peculiar disintegration of the granulomas, with extensive apoptosis and necrosis of their cells, occurring during the course of the infection and leading to the death of the animals within a few days of its onset. The survival time depends on the virulence of the infecting strain as well as on the dose and route of infection. Intravenously infected mice developed the typical lesions in hepatic granulomas whereas aerosol-infected animals developed them in the lung granulomas. At the onset of the development of pulmonary granuloma disintegration, extensive expansion of T cells, with intense up-regulation of activation markers, massive exacerbation of their ability to secrete IFN-gamma, and increased cytotoxic activity of both CD4(+) and CD8(+) T cells were observed. Forced expression of Bcl2 did not prevent the early death of infected TNF-deficient mice leading merely to a modest increase in survival times. The expression of the FasL on T cells was not affected but there was an intense up-regulation of the TRAIL in T cells and, in particular, myeloid cells. We thus show that an exacerbated immune response occurs in TNF-deficient hosts during M. avium infections that leads to enhanced IFN-gamma production and late up-regulation of TRAIL which may contribute to granuloma disintegration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025216     DOI: 10.4049/jimmunol.179.11.7702

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  The death-promoting molecule tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is not required for the development of peripheral lymphopenia or granuloma necrosis during infection with virulent Mycobacterium avium.

Authors:  M Borges; G T Rosa; R Appelberg
Journal:  Clin Exp Immunol       Date:  2011-04-06       Impact factor: 4.330

Review 2.  T cells in mycobacterial infection and disease.

Authors:  Andrea M Cooper
Journal:  Curr Opin Immunol       Date:  2009-07-29       Impact factor: 7.486

Review 3.  Cytokines in the balance of protection and pathology during mycobacterial infections.

Authors:  Egídio Torrado; Andrea M Cooper
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Reactivation of M. tuberculosis infection in trans-membrane tumour necrosis factor mice.

Authors:  Ivy Dambuza; Roanne Keeton; Nasiema Allie; Nai-Jen Hsu; Philippa Randall; Boipelo Sebesho; Lizette Fick; Valerie J F Quesniaux; Muazzam Jacobs
Journal:  PLoS One       Date:  2011-11-21       Impact factor: 3.240

5.  Endogenous cathelicidin production limits inflammation and protective immunity to Mycobacterium avium in mice.

Authors:  José Carlos Santos; Sandro Silva-Gomes; João Pedro Silva; Miguel Gama; Gustavo Rosa; Richard L Gallo; Rui Appelberg
Journal:  Immun Inflamm Dis       Date:  2013-10-31

6.  Lactoferricin Peptides Increase Macrophages' Capacity To Kill Mycobacterium avium.

Authors:  Tânia Silva; Ana C Moreira; Kamran Nazmi; Tânia Moniz; Nuno Vale; Maria Rangel; Paula Gomes; Jan G M Bolscher; Pedro N Rodrigues; Margarida Bastos; Maria Salomé Gomes
Journal:  mSphere       Date:  2017-08-30       Impact factor: 4.389

7.  Mycobacterium tuberculosis DosR Regulon Gene Rv2004c Encodes a Novel Antigen with Pro-inflammatory Functions and Potential Diagnostic Application for Detection of Latent Tuberculosis.

Authors:  Sankara Narayana Doddam; Vidyullatha Peddireddy; Niyaz Ahmed
Journal:  Front Immunol       Date:  2017-06-24       Impact factor: 7.561

8.  BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity.

Authors:  Getahun Abate; Fahreta Hamzabegovic; Christopher S Eickhoff; Daniel F Hoft
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.